Chaotropic Salt Composition for SARS-CoV-2 POC PCR Sample Prep
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PCR-based diagnostic methods for SARS-CoV-2 are time-consuming, require sophisticated equipment, and skilled personnel, making them unsuitable for rapid and cost-effective point-of-care testing, especially in resource-limited settings, and often result in false positives/negatives due to lower sensitivity and specificity compared to PCR tests.
Innovation Solution
A liquid composition containing a chaotropic salt, such as guanidinium thiocyanate, in specific concentrations to lyse and stabilize SARS-CoV-2, combined with RNAse inhibitors and nanoparticles coated with antibodies for sample preparation, enabling direct use of biological samples in point-of-care PCR analysis, reducing sample preparation time and enhancing diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional PCR-based diagnostic methods are used, then high sensitivity and specificity are achieved, but the testing process becomes time-consuming and requires sophisticated equipment and skilled personnel
Solution Approach 1:
The patent extracts and eliminates the need for complex PCR instrumentation by using a simplified chemical composition (chaotropic salt-based buffer with specific additives) that enables direct RNA extraction and amplification in a single tube, removing the requirement for sophisticated equipment while maintaining diagnostic accuracy
Solution Approach 2:
The chemical composition performs multiple functions simultaneously: it acts as a lysis buffer, RNA stabilization agent, and PCR reaction medium, eliminating the need for separate equipment steps and skilled operational procedures while maintaining high sensitivity and specificity
2Reliability
If traditional PCR-based diagnostic methods are used, then high sensitivity and specificity are achieved, but the testing time increases to several hours
Solution Approach 1:
The patent combines multiple separate steps (sample lysis, RNA extraction, and PCR amplification) into a single integrated reaction tube using a proprietary chemical composition, eliminating intermediate transfer steps and reducing total testing time from several hours to under 30 minutes while preserving diagnostic accuracy
Solution Approach 2:
The chemical composition is pre-formulated with all necessary components (chaotropic salt, stabilizers, and PCR reagents) in optimal concentrations, allowing direct addition to the sample without preliminary preparation steps, thereby reducing testing time while maintaining high sensitivity and specificity
3Reliability
If traditional PCR methods are used, then accurate detection is achieved, but the cost and operational complexity increase due to expensive instrumentation
Solution Approach 1:
The patent replaces expensive, reusable PCR instrumentation with a disposable, pre-formulated chemical composition that can be used in simple, low-cost reaction tubes, making accurate SARS-CoV-2 detection accessible in resource-limited settings while maintaining high sensitivity and specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for rapid, accurate, and cost-effective detection of SARS-CoV-2 with a single-step RNA isolation in under 5 minutes, achieving clinical sensitivity of >90% and specificity of 100%, significantly improving upon traditional PCR methods by minimizing false positives and negatives.
Implementation Method 1
a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 960 mM
Implementation Method 2
b) optionally one or more RNAse inhibitor
Data Source
AI summary
Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-CoV-2 or genetic variations (mutant) of SARS-CoV-2 wildtype in said sample by POC PCR comprising: a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 960 mM and b) optionally one or more RNAse inhibitor.